1
|
Dadon Y, Hecht Sagie L, Mimouni FB, Arad I, Mendlovic J. Vitamin D and Insulin-Dependent Diabetes: A Systematic Review of Clinical Trials. Nutrients 2024; 16:1042. [PMID: 38613075 PMCID: PMC11013464 DOI: 10.3390/nu16071042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2024] [Revised: 03/31/2024] [Accepted: 04/01/2024] [Indexed: 04/14/2024] Open
Abstract
(1) Background: Vitamin D supplementation after type 1 diabetes mellitus (T1DM) onset has led to conflicting results on beta-cell preservation. Aim: This paper presents a systematic review to verify whether randomized prospective controlled trials (RCTs) demonstrate that improved vitamin D status confers protection on T1DM. (2) Methods: A systematic review was conducted up until 18 January 2024 according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching MEDLINE, MEDLINE In-Process, Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials, using keywords "vitamin D", "type 1 diabetes", and "children". (3) Results: Following the above-mentioned search process, 408 articles in PubMed and 791 in Embase met inclusion criteria. After removing duplicates, 471 articles remained. After exclusion criteria, 11 RCTs remained. Because of major heterogeneity in design and outcomes, no meta-analyses were conducted, allowing only for qualitative analyses. There was no strong evidence that vitamin D supplementation has lasting effects on beta-cell preservation or glycemic control in new-onset T1DM. (4) Conclusions: More rigorous, larger studies are needed to demonstrate whether vitamin D improves beta-cell preservation or glycemic control in new-onset T1DM. Because T1DM may cause osteopenia, it is advisable that patients with new onset T1DM have adequate vitamin D stores.
Collapse
Affiliation(s)
- Yuval Dadon
- Ministry of Health, Jerusalem 9101002, Israel (J.M.)
| | | | - Francis B. Mimouni
- Leumit Health Services Research Center, Tel Aviv 6473817, Israel;
- Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
| | - Iris Arad
- School of Medicine, Hebrew University of Jerusalem, Jerusalem 9190500, Israel
| | - Joseph Mendlovic
- Ministry of Health, Jerusalem 9101002, Israel (J.M.)
- Shaare Zedek Medical Center, Affiliated with the Hadassah-Hebrew University School of Medicine, Jerusalem 9103102, Israel
| |
Collapse
|
2
|
Mendlovic J, Dadon Y, Mimouni FB. A Statistical Approach to the High Mortality Rate of Israeli Citizens Held Hostage in Gaza. Isr Med Assoc J 2024; 26:141-142. [PMID: 38493323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/18/2024]
Abstract
BACKGROUND According to Hamas sources, many Israeli hostages in Gaza were killed by indiscriminate Israeli airstrikes, together with a large number of Palestinian citizens. OBJECTIVES To verify whether the estimated death rate of Israeli hostages was similar to the estimated death rate of Gaza citizens from these acts of war. METHODS We used two estimates of hostage death rates, one obtained from Israeli intelligence sources, and one published by a Hamas spokesperson. We used the Palestinian casualty rates published by the Palestinian Ministry of Health. We compared death rates using Fisher's exact test. RESULTS By 30 December 2023, the rate of Israeli hostage death was 23/238 (9.7%) according to Israeli intelligence sources, and 60/238 (25.2%) according to Hamas. Both figures are strikingly and significantly higher than the death rate among Palestinians, estimated to be 19,667/2.2 million (0.89%) by 19 December 2023 (P < 0.0001). CONCLUSIONS Israeli airstrikes as the cause of death of Israeli hostages are implausible unless they were specifically exposed to these strikes more than Palestinian citizens.
Collapse
Affiliation(s)
- Joseph Mendlovic
- Deputy Director Office, Ministry of Health, Jerusalem, Israel, Department of Pediatrics, Shaare Zedek Medical Center, affiliated with the Hadassah-Hebrew University School of Medicine, Jerusalem, Israel
| | - Yuval Dadon
- Deputy Director Office, Ministry of Health, Jerusalem, Israel
| | - Francis B Mimouni
- Leumit Health Services and Research Institute, Tel Aviv, Israel, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
3
|
Eisen L, Mor Z, Madar M, Rabinovitch R, Dadon Y, Sheffer R, Kaliner E, Goldstein L. Hepatitis C Virus Elimination Program among Prison Inmates, Israel. Emerg Infect Dis 2023; 29:2358-2361. [PMID: 37877627 PMCID: PMC10617329 DOI: 10.3201/eid2911.230728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2023] Open
Abstract
The Israeli Prison Services implemented a hepatitis C virus (HCV) elimination program in 2020. Inmates considered high risk for HCV were offered serology; HCV-seropositive participants were offered HCV RNA testing. Among participants, 7.0% had detectable HCV RNA and were offered antiviral drug therapy. This program reduced HCV burden among incarcerated persons.
Collapse
Affiliation(s)
| | | | - Miriam Madar
- Ministry of Health, Tel-Aviv Department of Health, Tel Aviv, Israel (L. Eisen, R. Sheffer)
- Ashkelon Academic College, Ashkelon, Israel (Z. Mor)
- Central Department of Health, Ministry of Health, Ramla, Israel (Z. Mor, E. Kaliner)
- Israel Prison Service, Israel (M. Madar, R. Rabinovitch, L. Goldstein)
- Deputy Director Office, Ministry of Health, Jerusalem, Israel (Y. Dadon)
| | - Ron Rabinovitch
- Ministry of Health, Tel-Aviv Department of Health, Tel Aviv, Israel (L. Eisen, R. Sheffer)
- Ashkelon Academic College, Ashkelon, Israel (Z. Mor)
- Central Department of Health, Ministry of Health, Ramla, Israel (Z. Mor, E. Kaliner)
- Israel Prison Service, Israel (M. Madar, R. Rabinovitch, L. Goldstein)
- Deputy Director Office, Ministry of Health, Jerusalem, Israel (Y. Dadon)
| | - Yuval Dadon
- Ministry of Health, Tel-Aviv Department of Health, Tel Aviv, Israel (L. Eisen, R. Sheffer)
- Ashkelon Academic College, Ashkelon, Israel (Z. Mor)
- Central Department of Health, Ministry of Health, Ramla, Israel (Z. Mor, E. Kaliner)
- Israel Prison Service, Israel (M. Madar, R. Rabinovitch, L. Goldstein)
- Deputy Director Office, Ministry of Health, Jerusalem, Israel (Y. Dadon)
| | - Rivka Sheffer
- Ministry of Health, Tel-Aviv Department of Health, Tel Aviv, Israel (L. Eisen, R. Sheffer)
- Ashkelon Academic College, Ashkelon, Israel (Z. Mor)
- Central Department of Health, Ministry of Health, Ramla, Israel (Z. Mor, E. Kaliner)
- Israel Prison Service, Israel (M. Madar, R. Rabinovitch, L. Goldstein)
- Deputy Director Office, Ministry of Health, Jerusalem, Israel (Y. Dadon)
| | - Ehud Kaliner
- Ministry of Health, Tel-Aviv Department of Health, Tel Aviv, Israel (L. Eisen, R. Sheffer)
- Ashkelon Academic College, Ashkelon, Israel (Z. Mor)
- Central Department of Health, Ministry of Health, Ramla, Israel (Z. Mor, E. Kaliner)
- Israel Prison Service, Israel (M. Madar, R. Rabinovitch, L. Goldstein)
- Deputy Director Office, Ministry of Health, Jerusalem, Israel (Y. Dadon)
| | - Liav Goldstein
- Ministry of Health, Tel-Aviv Department of Health, Tel Aviv, Israel (L. Eisen, R. Sheffer)
- Ashkelon Academic College, Ashkelon, Israel (Z. Mor)
- Central Department of Health, Ministry of Health, Ramla, Israel (Z. Mor, E. Kaliner)
- Israel Prison Service, Israel (M. Madar, R. Rabinovitch, L. Goldstein)
- Deputy Director Office, Ministry of Health, Jerusalem, Israel (Y. Dadon)
| |
Collapse
|
4
|
Wedemeyer H, Tergast TL, Lazarus JV, Razavi H, Bakoyannis K, Baptista-Leite R, Bartoli M, Bruggmann P, Buşoi CS, Buti M, Carballo M, Castera L, Colombo M, Coutinho RS, Dadon Y, Esmat G, Esteban R, Farran JC, Gillyon-Powell M, Goldberg D, Hutchinson S, Janssen HLA, Kalamitsis G, Kondili LA, Lambert JS, Marinho RT, Maticic M, Patricello A, Peck-Radosavljevic M, Pol S, Poljak M, Pop C, Sokol T, Sypsa V, Tözün N, Younossi Z, Aghemo A, Papatheodoridis GV, Hatzakis A. Securing wider EU commitment to the elimination of hepatitis C virus. Liver Int 2023; 43:276-291. [PMID: 36196744 DOI: 10.1111/liv.15446] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 09/04/2022] [Accepted: 09/29/2022] [Indexed: 01/25/2023]
Abstract
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programmes-from the municipality level to the EU level-were launched, resulting in an overall decrease in viremic HCV infections and liver-related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID-19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct-acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost-saving than treating and caring for patients with liver-related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale-up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the third EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and reported the 'Call-to-Action' statement supported by all the major relevant European associations in the field.
Collapse
Affiliation(s)
- Heiner Wedemeyer
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - Tammo L Tergast
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - Jeffrey V Lazarus
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - Homie Razavi
- Center for Disease Analysis Foundation, Lafayette, Colorado, USA
| | | | - Ricardo Baptista-Leite
- Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.,Institute of Health Sciences, Católica University of Portugal, Lisbon, Portugal
| | | | | | | | - Maria Buti
- Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III, Barcelona, Spain
| | - Manuel Carballo
- International Centre for Migration, Health and Development, Geneva, Switzerland
| | - Laurent Castera
- Department of Hepatology, Hôpital Beaujon AP-HP-University of Paris-VII, Clichy, France
| | | | | | | | - Gamal Esmat
- Endemic Medicine and Department of HepatoGastroenterology Faculty of Medicine, Cairo University Hospital, Cairo, Egypt
| | - Rafael Esteban
- Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III, Barcelona, Spain
| | | | | | | | - Sharon Hutchinson
- School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
| | - Harry L A Janssen
- Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
| | | | | | - John S Lambert
- Mater Misericordiae University Hospital, and UCD School of Medicine, Dublin, Ireland
| | - Rui Tato Marinho
- Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal
| | - Mojca Maticic
- Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre, Ljubljana, Slovenia.,Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | | | - Markus Peck-Radosavljevic
- Department of Internal Medicine and Gastroenterology (IMuG) Hepatology, Endocrinology, Rheumatology and Nephrology with Centralized Emergency Department (ZAE), Klagenfurt, Austria
| | - Stanislas Pol
- Department of Hepatology, Université de Paris, APHP, Hopital Cochin, Paris, France
| | - Mario Poljak
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Ljubljana, Ljubljana, Slovenia
| | - Cora Pop
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | | | - Vana Sypsa
- Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - Nurdan Tözün
- Department of Gastroenterology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey
| | - Zobair Younossi
- Department of Medicine, Inova Health Fairfax Medical Campus, Fairfax, Virginia, USA
| | - Alessio Aghemo
- Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Clinical and Research Hospital, Milan, Italy
| | - George V Papatheodoridis
- Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Athens, Greece
| | - Angelos Hatzakis
- Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece
| |
Collapse
|
5
|
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler 2022; 28:608-619. [PMID: 34378456 DOI: 10.1177/13524585211032803] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). OBJECTIVE Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS CONCERTO was a randomized, double-blind, placebo-controlled, phase-3 study. RRMS patients were randomized 1:1:1 to receive once-daily oral laquinimod 0.6 or 1.2 mg or placebo for ⩽24 months (n = 727, n = 732, and n = 740, respectively). Primary endpoint was time to 3-month confirmed disability progression (CDP). The laquinimod 1.2-mg dose arm was discontinued (1 January 2016) due to cardiovascular events at high doses. Safety was monitored throughout the study. RESULTS CONCERTO did not meet the primary endpoint of significant effect with laquinimod 0.6-mg versus placebo on 3-month CDP (hazard ratio: 0.94; 95% confidence interval: 0.67-1.31; p = 0.706). Secondary endpoint p values were nominal and non-inferential. Laquinimod 0.6 mg demonstrated 40% reduction in percent brain volume change from baseline to Month 15 versus placebo (p < 0.0001). The other secondary endpoint, time to first relapse, and annualized relapse rate (an exploratory endpoint) were numerically lower (both, p = 0.0001). No unexpected safety findings were reported with laquinimod 0.6 mg. CONCLUSION Laquinimod 0.6 mg demonstrated only nominally significant effects on clinical relapses and magnetic resonance imaging (MRI) outcomes and was generally well tolerated. CLINICAL TRIAL REGISTRATION NUMBER ClinicalTrials.gov (NCT01707992).
Collapse
Affiliation(s)
- Giancarlo Comi
- Vita-Salute San Raffaele University, Milan, Italy/Centro Sclerosi Multipla, Presidio Ospedaliero di Gallarate, Gallarate, Italy
| | - Yuval Dadon
- Teva Pharmaceutical Industries, Netanya, Israel
| | | | | | | | | | - Alexey Boyko
- Pirogov Russian National Research University and Department of Neuroimmunology of the Federal Center of Cerebrovascular Pathology and Stroke, Moscow, Russia
| | - Patrick Vermersch
- Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France
| | - Tjalf Ziemssen
- Center of Clinical Neuroscience, University Hospital, Dresden, Germany
| | - Xavier Montalban
- Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada/Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Fred D Lublin
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Maria A Rocca
- Vita-Salute San Raffaele University, Milan, Italy/Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | | | | | - Massimo Filippi
- Vita-Salute San Raffaele University, Milan, Italy/Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy/Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
6
|
Dadon Y, Haas EJ, Kaliner E, Anis E, Singer SR, Atiya-Nasagi Y, Cohen-Dar M, Avramovich E, King R, Sued O, Goshen T, Amit S, Miskin I, Gino E, Yishai R, Sheffer R, Grotto I, Moran-Gilad J. Outbreak of human leptospirosis linked to contaminated water bodies in Northern Israel, June to August 2018. Euro Surveill 2018; 23:1800486. [PMID: 30255835 PMCID: PMC6157089 DOI: 10.2807/1560-7917.es.2018.23.38.1800486] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
We report preliminary findings of a large outbreak of human leptospirosis with 36 confirmed/probable and 583 suspected cases from June-August 2018, linked to contaminated water bodies in Northern Israel. There was a travel-associated case in Germany; additional cases are being investigated in other countries. The presumed chain of transmission, implicating wild boar and cattle, raises multiple challenges for risk assessment, risk management and risk communication currently being addressed by a public health response team.
Collapse
Affiliation(s)
- Yuval Dadon
- Ministry of Health Directorate, Jerusalem, Israel,The Division of Epidemiology, Public Health Services, Ministry of Health, Jerusalem, Israel,These authors contributed equally to the study
| | - Eric J. Haas
- The Division of Epidemiology, Public Health Services, Ministry of Health, Jerusalem, Israel,These authors contributed equally to the study,School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Ehud Kaliner
- Public Health Services, Ministry of Health, Jerusalem, Israel
| | - Emilia Anis
- The Division of Epidemiology, Public Health Services, Ministry of Health, Jerusalem, Israel,Braun School of Public Health and Community Medicine, Hebrew University and Hadassah, Jerusalem, Israel
| | - Shepherd Roee Singer
- The Division of Epidemiology, Public Health Services, Ministry of Health, Jerusalem, Israel,Braun School of Public Health and Community Medicine, Hebrew University and Hadassah, Jerusalem, Israel
| | | | | | | | - Roni King
- Nature and Parks Authority, Jerusalem, Israel
| | - Oded Sued
- Mekorot Central Laboratory, Eshkol Site, National Water Company, Israel
| | - Tamir Goshen
- Israeli Veterinary Services, Ministry of Agriculture and Rural Development, Beit Dagan, Israel
| | | | - Ian Miskin
- Jerusalem District, Clalit Health Services, Jerusalem, Israel
| | - Efrat Gino
- Public Health Laboratory, Haifa District, Ministry of Health, Haifa, Israel
| | - Ruth Yishai
- Public Health Services, Ministry of Health, Jerusalem, Israel
| | - Rivka Sheffer
- Public Health Services, Ministry of Health, Jerusalem, Israel
| | - Itamar Grotto
- Ministry of Health Directorate, Jerusalem, Israel,School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Jacob Moran-Gilad
- Ministry of Health Directorate, Jerusalem, Israel,School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Public Health Services, Ministry of Health, Jerusalem, Israel
| |
Collapse
|
7
|
Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V. Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. Int J MS Care 2017; 19:16-24. [PMID: 28243182 DOI: 10.7224/1537-2073.2015-024] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND Laquinimod 0.6 mg is a once-daily, oral, disease-modifying therapy in development for the treatment of multiple sclerosis (MS) that was investigated in two double-blind, placebo-controlled, phase 3 trials: ALLEGRO and BRAVO. METHODS Data from these studies were pooled to assess the safety profile of laquinimod versus placebo. Adverse events (AEs), laboratory value changes, and potential risks identified in preclinical studies were evaluated in participants in ALLEGRO and BRAVO treated with at least one dose of laquinimod or matching placebo (1:1 random assignment). RESULTS In total, 1988 patients received at least one dose of study drug (laquinimod: n = 983 [mean ± SD duration, 639 ± 190 days]; placebo: n = 1005 [mean ± SD duration, 627 ± 198 days]). Early terminations due to AEs were infrequent (laquinimod: 6.4%; placebo: 4.7%). Death was reported in four patients (laquinimod: n = 1; placebo: n = 3). Rates of serious AEs (including malignancies, infections, and cardiovascular AEs) were similar between groups. The most common AEs identified with laquinimod use were back and neck pain and appendicitis. Laquinimod was also associated with asymptomatic changes in liver enzyme levels, fibrinogen levels, and hematologic parameters that followed a consistent temporal pattern: mild, nonprogressive, and occurring within 90 days of treatment initiation, then stabilizing or reverting to baseline levels during continued treatment. CONCLUSIONS Data from these pivotal laquinimod studies demonstrate a safety profile comprising benign or manageable AEs and asymptomatic laboratory findings with a clear temporal pattern. Potential risks noted in preclinical studies were not observed.
Collapse
|
8
|
Neudorfer M, Goldshtein I, Shamai-Lubovitz O, Chodick G, Dadon Y, Shalev V. Ocular Adverse Effects of Systemic Treatment With Isotretinoin. ACTA ACUST UNITED AC 2012; 148:803-8. [DOI: 10.1001/archdermatol.2012.352] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|